Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 128

1.

Genetic variation in dopaminergic pathways and short-term effectiveness of the nicotine patch.

Johnstone EC, Yudkin PL, Hey K, Roberts SJ, Welch SJ, Murphy MF, Griffiths SE, Walton RT.

Pharmacogenetics. 2004 Feb;14(2):83-90.

PMID:
15077009
2.

Association between polymorphisms in dopamine metabolic enzymes and tobacco consumption in smokers.

McKinney EF, Walton RT, Yudkin P, Fuller A, Haldar NA, Mant D, Murphy M, Welsh KI, Marshall SE.

Pharmacogenetics. 2000 Aug;10(6):483-91.

PMID:
10975602
3.

Dopamine D4 receptors and the risk of cigarette smoking in African-Americans and Caucasians.

Shields PG, Lerman C, Audrain J, Bowman ED, Main D, Boyd NR, Caporaso NE.

Cancer Epidemiol Biomarkers Prev. 1998 Jun;7(6):453-8.

4.

Distinct haplogenotypes of the dopamine D2 receptor gene are associated with non-smoking behaviour and daily cigarette consumption.

Wernicke C, Reese J, Kraschewski A, Winterer G, Rommelspacher H, Gallinat J.

Pharmacopsychiatry. 2009 Mar;42(2):41-50. doi: 10.1055/s-0028-1085444. Epub 2009 Mar 23.

PMID:
19308877
5.

A review of the efficacy of smoking-cessation pharmacotherapies in nonwhite populations.

Robles GI, Singh-Franco D, Ghin HL.

Clin Ther. 2008 May;30(5):800-12. doi: 10.1016/j.clinthera.2008.05.010. Review.

PMID:
18555928
6.

Association of the mu-opioid receptor gene with smoking cessation.

Munafò MR, Elliot KM, Murphy MF, Walton RT, Johnstone EC.

Pharmacogenomics J. 2007 Oct;7(5):353-61. Epub 2007 Jan 16.

PMID:
17224915
7.

Does the DRD2-Taq1 A polymorphism influence treatment response to bupropion hydrochloride for reduction of the nicotine withdrawal syndrome?

David SP, Niaura R, Papandonatos GD, Shadel WG, Burkholder GJ, Britt DM, Day A, Stumpff J, Hutchison K, Murphy M, Johnstone E, Griffiths SE, Walton RT.

Nicotine Tob Res. 2003 Dec;5(6):935-42.

PMID:
14668077
8.

Prospective association of dopamine-related polymorphisms with smoking cessation in general care.

Breitling LP, Twardella D, Hoffmann MM, Witt SH, Treutlein J, Brenner H.

Pharmacogenomics. 2010 Apr;11(4):527-36. doi: 10.2217/pgs.10.1.

PMID:
20350135
9.

Lack of association of DRD2 rs1800497 (Taq1A) polymorphism with smoking cessation in a nicotine replacement therapy randomized trial.

Munafò MR, Johnstone EC, Murphy MF, Aveyard P.

Nicotine Tob Res. 2009 Apr;11(4):404-7. doi: 10.1093/ntr/ntp007. Epub 2009 Mar 8.

PMID:
19273465
11.

Triple-combination pharmacotherapy for medically ill smokers: a randomized trial.

Steinberg MB, Greenhaus S, Schmelzer AC, Bover MT, Foulds J, Hoover DR, Carson JL.

Ann Intern Med. 2009 Apr 7;150(7):447-54.

PMID:
19349630
12.
13.

Interaction between variation in the D2 dopamine receptor (DRD2) and the neuronal calcium sensor-1 (FREQ) genes in predicting response to nicotine replacement therapy for tobacco dependence.

Dahl JP, Jepson C, Levenson R, Wileyto EP, Patterson F, Berrettini WH, Lerman C.

Pharmacogenomics J. 2006 May-Jun;6(3):194-9.

PMID:
16402081
14.

[Study on the association between smoking behavior and dopamine receptor D2 gene polymorphisms among lung cancer cases].

Qi J, Tan W, Xing D, Miao X, Lin D.

Zhonghua Liu Xing Bing Xue Za Zhi. 2002 Oct;23(5):370-3. Chinese.

PMID:
12482370
15.

Meta-analysis of studies investigating one-year effectiveness of transdermal nicotine patches for smoking cessation.

Myung SK, Yoo KY, Oh SW, Park SH, Seo HG, Hwang SS, Park SK.

Am J Health Syst Pharm. 2007 Dec 1;64(23):2471-6.

PMID:
18029953
16.

Dopamine receptor genes (DRD2, DRD3 and DRD4) and gene-gene interactions associated with smoking-related behaviors.

Vandenbergh DJ, O'Connor RJ, Grant MD, Jefferson AL, Vogler GP, Strasser AA, Kozlowski LT.

Addict Biol. 2007 Mar;12(1):106-16.

PMID:
17407504
17.

Genetic variation in mu-opioid-receptor-interacting proteins and smoking cessation in a nicotine replacement therapy trial.

Ray R, Jepson C, Wileyto EP, Dahl JP, Patterson F, Rukstalis M, Pinto A, Berrettini W, Lerman C.

Nicotine Tob Res. 2007 Nov;9(11):1237-41.

PMID:
17978999
18.

Genetic variation in three candidate genes and nicotine dependence, withdrawal and smoking cessation in hospitalized patients.

De Ruyck K, Nackaerts K, Beels L, Werbrouck J, De Volder A, Meysman M, Salhi B, Van Meerbeeck J, Thierens H.

Pharmacogenomics. 2010 Aug;11(8):1053-63. doi: 10.2217/pgs.10.75.

PMID:
20712524
19.

The effects of the DRD2 polymorphism on smoking cessation and negative affect: evidence for a pharmacogenetic effect on mood.

Cinciripini P, Wetter D, Tomlinson G, Tsoh J, De Moor C, Cinciripini L, Minna J.

Nicotine Tob Res. 2004 Apr;6(2):229-39.

PMID:
15203796
20.

Effects of dopamine transporter and receptor polymorphisms on smoking cessation in a bupropion clinical trial.

Lerman C, Shields PG, Wileyto EP, Audrain J, Hawk LH Jr, Pinto A, Kucharski S, Krishnan S, Niaura R, Epstein LH.

Health Psychol. 2003 Sep;22(5):541-8.

PMID:
14570538

Supplemental Content

Support Center